Adam Scott Levy is CFO & Secretary at Mineralys Therapeutics, Inc. (MLYS). They have made 6 open-market trades across 2 companies since 2017, most recently 2026-02-19.
CIK 0001693134
3 open-market purchases totalling $152K since 2017, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MLYS | 48,538 | $825K |
| MGEN | 10,540 | $243K |
| Total | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-02-20 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MLYS | SELL | 2026-01-12 | 2026-01-13 | $32.14 | $346K | +2.6% | -13.5% | -15.7% |
| MLYS | SELL | 2025-11-11 | 2025-11-13 | $44.71 | $8.7M | -1.3% | -15.7% | -30.3% |
| MLYS | SELL · 10b5-1 | 2025-10-13 | 2025-10-15 | $42.01 | $904K | -6.2% | -5.5% | -23.8% |
| MLYS | SELL | 2025-07-28 | 2025-07-30 | $14.59 | $1.4M | -7.2% | +8.9% | +186.2% |
| MLYS | SELL · 10b5-1 | 2025-07-11 | 2025-07-15 | $14.45 | $311K | -1.6% | -2.9% | +195.9% |
| MLYS | SELL · 10b5-1 | 2025-04-11 | 2025-04-15 | $12.06 | $259K | -0.4% | +12.8% | +10.3% |
| MLYS | SELL · 10b5-1 | 2025-01-13 | 2025-01-15 | $9.09 | $195K | +0.6% | +4.5% | +41.6% |
| MLYS | SELL · 10b5-1 | 2024-10-11 | 2024-10-15 | $13.57 | $292K | -1.7% | -12.1% | -32.4% |
| MLYS | SELL · 10b5-1 | 2024-07-11 | 2024-07-12 | $13.14 | $283K | -6.3% | -22.7% | -8.5% |
| MLYS | SELL · 10b5-1 | 2024-06-11 | 2024-06-13 | $12.94 | $2.5M | -10.5% | +17.7% | -6.1% |
| MLYS | BUY | 2023-02-14 | 2023-02-16 | $16.00 | $100K | +0.1% | -16.3% | -9.7% |
| MGEN | BUY | 2018-02-13 | 2018-02-13 | $5.50 | $50K | +1.3% | +30.5% | +38.9% |
| MGEN | BUY | 2017-06-22 | 2017-06-23 | $7.55 | $2K | +56.3% | +77.5% | +8.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.